Single Dose PK of IV Tedizolid Phosphate in Morbidly Obese and Non-Obese Adults

Summary

This is an open label, single-dose, pharmacokinetic study in 9 obese and 9 age-, sex-, ideal body weight- matched non-obese subjects. Qualifying subjects who have completed an informed consent will receive a single intravenous dose of tedizolid with the collection of 11 blood samples over 72 hours post dose.

Timeline

Start

2015-03

Primary completion

2015-09

Completion

2015-12

Publications

• Results Pai MP. Pharmacokinetics of Tedizolid in Morbidly Obese and Covariate-Matched Nonobese Adults. Antimicrob Agents Chemother. 2016 Jul 22;60(8):4585-9. doi: 10.1128/AAC.00682-16. Print 2016 Aug.

Drugs

Indications